PRODUCT TYPES – Page 34

Half-life deviation during transport to clinic: CAPA under time-critical constraints

Identifying early symptoms or signals related to half-life deviations is essential for timely intervention. Symptoms might include:Click to read the full article.

Biosimilar lot-to-lot variability trend (OOT) during comparability protocol execution: how to handle outliers and statistics without triggering inspection findings

The first step in addressing biosimilar lot-to-lot variability trends during comparability execution is to identify the symptoms or signals that indicate an out-of-trend (OOT) occurrence. Symptoms can manifest in multiple…

Residue limit non-compliance during inspection prep: GMP investigation and CAPA

In the context of residue limit non-compliance during inspection preparation, several key symptoms may indicate underlying issues:Click to read the full article.

Transport time excursion during transport to clinic: patient safety assessment

Identifying symptoms early in the transport process is crucial for effective management of excursions. Common signals of a transport time excursion include:Click to read the full article.

Biosimilar reference standard qualification gap during CPV trending review: how to handle outliers and statistics without triggering inspection findings

Recognizing signals that indicate potential qualification gaps during CPV trending reviews is the first step in managing deviations effectively. Common symptoms include:Click to read the full article.

Assay OOS during inspection prep: risk assessment for animal and food safety

Identifying OOS results effectively requires keen observation and systematic documentation. Symptoms indicating OOS assay results may manifest in various forms, including:Click to read the full article.

Half-life deviation during radiopharma production: CAPA under time-critical constraints

In a pharmaceutical manufacturing setting, particularly with radiopharmaceuticals, it is crucial to monitor for specific symptoms that may indicate a half-life deviation. Typically, these signals manifest in several ways:Click to…

Biosimilar lot-to-lot variability trend (OOT) during biosimilar development: inspection-ready evidence pack for comparability and lifecycle management

The first step in any investigation of biosimilar lot-to-lot variability is identifying the symptoms or signals that indicate a potential issue. Symptoms may arise during routine testing, stability studies, or…

Labeling deviation in veterinary product manufacturing: GMP investigation and CAPA

Symptoms of labeling deviations can manifest in various forms, requiring attention from quality control (QC) and quality assurance (QA) teams. Typical signals include:Click to read the full article.

Radiochemical purity OOS during dispensing: patient safety assessment

Recognizing symptoms associated with OOS results concerning radiochemical purity is pivotal. Typically, symptoms manifest as deviations from expected quality specifications during the final stages of dispensing. Possible signals include:Click to…

Biosimilar process change without bridging study after cell line or upstream change: risk assessment for critical quality attributes and clinical impact

Detecting deviations early is vitally important in pharmaceutical manufacturing, especially for biosimilars where the expected similarity is crucial for efficacy and safety. Symptoms of a problematic process change may manifest…

Stability failure in veterinary product manufacturing: GMP investigation and CAPA

Identifying symptoms of stability failure often starts with routine monitoring and testing results. Symptoms may include:Click to read the full article.